{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:56:53Z","timestamp":1776376613524,"version":"3.51.2"},"reference-count":54,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/01443615.2023.2204940","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T16:11:57Z","timestamp":1684167117000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels"],"prefix":"10.1080","volume":"43","author":[{"given":"Meiling","family":"Zhang","sequence":"first","affiliation":[{"name":"The Second Department of Oncology, Huoshan County Hospital, Huoshan County","place":["Lu\u2019an City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The People\u2019s Hospital of Chizhou","place":["Chizou City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology","place":["Hefei City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Taihe County Hospital of Traditional Chinese Medicine, Taihe County","place":["Fuyang City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinkuan","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fuyang Cancer Hospital","place":["Fuyang City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianping","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology","place":["Hefei City, P.R. China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000809"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.10.028"},{"key":"e_1_3_3_4_1","first-page":"484","volume-title":"Immunotherapy for platinum-resistant ovarian cancer","author":"Bogani G.","year":"2020","unstructured":"Bogani, G., et\u00a0al., 2020. Immunotherapy for platinum-resistant ovarian cancer. Gynecologic Oncology, 158 (2), 484\u2013488."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-017-0058-9"},{"key":"e_1_3_3_6_1","first-page":"1325","volume-title":"B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites","author":"Cui S.","year":"2012","unstructured":"Cui, S., et\u00a0al., 2012. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncology Reports, 28 (4), 1325\u20131331."},{"key":"e_1_3_3_7_1","first-page":"27","volume-title":"Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients","author":"Dalal V.","year":"2018","unstructured":"Dalal, V., et\u00a0al., 2018. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clinica Chimica Acta, 482, 27\u201332."},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5680-7"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001640"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajo.13297"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0875-x"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15970"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094871"},{"key":"e_1_3_3_14_1","first-page":"83","volume-title":"Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer","author":"Ghoneum A.","year":"2021","unstructured":"Ghoneum, A., et\u00a0al., 2021. Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. Seminars in Cancer Biology, 77, 83\u201398."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000016"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0042"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.37455"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2015.1036739"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188361"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02353-x"},{"issue":"5","key":"e_1_3_3_21_1","first-page":"495","article-title":"Cytogenetic analysis of epithelial ovarian cancer\u2019s stem cells: an overview on new diagnostic and therapeutic perspectives","volume":"36","author":"Lagana A. S.","year":"2015","unstructured":"Lagana, A. S., et\u00a0al., 2015. Cytogenetic analysis of epithelial ovarian cancer\u2019s stem cells: an overview on new diagnostic and therapeutic perspectives. European Journal of Gynaecological Oncology, 36 (5), 495\u2013505.","journal-title":"European Journal of Gynaecological Oncology"},{"key":"e_1_3_3_22_1","first-page":"582","volume-title":"Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma","author":"Lemoine L.","year":"2017","unstructured":"Lemoine, L., Sugarbaker, P. and Van der Speeten, K., 2017. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. International Journal of Hyperthermia, 33 (5), 582\u2013592."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-021-00915-9"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0143"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-022-02621-2"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2021.0079"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111434044"},{"issue":"1","key":"e_1_3_3_28_1","article-title":"Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer","volume":"19","author":"Mamguem K. A.","year":"2021","unstructured":"Mamguem K., A., et\u00a0al., 2021. Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer. Health and Quality of Life Outcomes, 19 (1), 56.","journal-title":"Health and Quality of Life Outcomes"},{"key":"e_1_3_3_29_1","article-title":"The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects","author":"Mao C. L.","year":"2022","unstructured":"Mao, C. L., Seow, K. M. and Chen, K. H., 2022. The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. International Journal of Molecular Sciences, 23 (13), 6911.","journal-title":"International Journal of Molecular Sciences, 23 (13), 6911."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0602-0"},{"issue":"6","key":"e_1_3_3_31_1","first-page":"44","article-title":"PARP inhibition: A promising therapeutic target in ovarian cancer","volume":"61","author":"Musella A.","year":"2015","unstructured":"Musella, A., et\u00a0al., 2015. PARP inhibition: A promising therapeutic target in ovarian cancer. Cellular and Molecular Biology, 61 (6), 44\u201361.","journal-title":"Cellular and Molecular Biology"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000448942"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2021.126865"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111496"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174318"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2019.1691222"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.73"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23572"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14112"},{"key":"e_1_3_3_40_1","first-page":"374","volume-title":"REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","author":"Sjoquist K. M.","year":"2021","unstructured":"Sjoquist, K. M., et\u00a0al., 2021. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. Gynecology Oncology, 161 (2), 374\u2013381."},{"key":"e_1_3_3_41_1","first-page":"1553","volume-title":"Malignant ascites in ovarian cancer and the role of targeted therapeutics","author":"Smolle E.","year":"2014","unstructured":"Smolle, E., Taucher, V. and Haybaeck, J., 2014. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Research, 34 (4), 1553\u20131561."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.58979"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-013-2868-y"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-018-5006-z"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.06.005"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.12.013"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12393"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1326"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6619730"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4414"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5RU0222-082R"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0292-1"},{"issue":"4","key":"e_1_3_3_55_1","first-page":"575","article-title":"Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19","volume":"68","author":"Zhao L.","year":"2021","unstructured":"Zhao, L., et\u00a0al., 2021. Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19. Acta Biochimica Polonica, 68 (4), 575\u2013582.","journal-title":"Acta Biochimica Polonica"}],"container-title":["Journal of Obstetrics and Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/01443615.2023.2204940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T13:50:59Z","timestamp":1757685059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/01443615.2023.2204940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/01443615.2023.2204940"],"URL":"https:\/\/doi.org\/10.1080\/01443615.2023.2204940","relation":{},"ISSN":["0144-3615","1364-6893"],"issn-type":[{"value":"0144-3615","type":"print"},{"value":"1364-6893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijog20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijog20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2204940"}}